Patents by Inventor Peter Tsvetkov
Peter Tsvetkov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230115675Abstract: Provided herein are methods and compositions related to the treatment of cancer using copper ionophores.Type: ApplicationFiled: February 26, 2021Publication date: April 13, 2023Inventors: Todd R. Golub, Peter Tsvetkov
-
Patent number: 11092602Abstract: In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating the level of expression or activity of a subunit of the 19S proteasome in the cell. In some aspects, cells in which the level of a 19S subunit is modulated, e.g., reduced, are provided. In some aspects, methods of identifying agents that reduce proteasome inhibitor resistance are provided. In some aspects, methods of classifying cancers according to predicted proteasome inhibitor resistance are provided. In some aspects, methods of killing or inhibiting proliferation of cancer cells, e.g., proteasome inhibitor resistant cancer cells, are provided. In some aspects, methods of treating cancer, e.g., proteasome inhibitor resistant cancer, are provided.Type: GrantFiled: July 6, 2016Date of Patent: August 17, 2021Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.Inventors: Peter Tsvetkov, Sandro Santagata, Susan Lindquist
-
Patent number: 10155949Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: December 7, 2017Date of Patent: December 18, 2018Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20180353445Abstract: In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating the level of expression or activity of a subunit of the 19S proteasome in the cell. In some aspects, cells in which the level of a 19S subunit is modulated, e.g., reduced, are provided. In some aspects, methods of identifying agents that reduce proteasome inhibitor resistance are provided. In some aspects, methods of classifying cancers according to predicted proteasome inhibitor resistance are provided. In some aspects, methods of killing or inhibiting proliferation of cancer cells, e.g., proteasome inhibitor resistant cancer cells, are provided. In some aspects, methods of treating cancer, e.g., proteasome inhibitor resistant cancer, are provided.Type: ApplicationFiled: January 12, 2018Publication date: December 13, 2018Inventors: Peter Tsvetkov, Sandro Santagata, Susan Lindquist
-
Publication number: 20180306796Abstract: In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating the level of expression or activity of a subunit of the 19S proteasome in the cell. In some aspects, cells in which the level of a 19S subunit is modulated, e.g., reduced, are provided. In some aspects, methods of identifying agents that reduce proteasome inhibitor resistance are provided. In some aspects, methods of classifying cancers according to predicted proteasome inhibitor resistance are provided. In some aspects, methods of killing or inhibiting proliferation of cancer cells, e.g., proteasome inhibitor resistant cancer cells, are provided. In some aspects, methods of treating cancer, e.g., proteasome inhibitor resistant cancer, are provided.Type: ApplicationFiled: July 6, 2016Publication date: October 25, 2018Inventors: Peter Tsvetkov, Sandro Santagata, Susan Lindquist
-
Publication number: 20180087057Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: December 7, 2017Publication date: March 29, 2018Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Patent number: 9840711Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: February 27, 2017Date of Patent: December 12, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20170175127Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: February 27, 2017Publication date: June 22, 2017Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef SHAUL, Peter TSVETKOV, Julia ADLER
-
Patent number: 9579339Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: September 27, 2015Date of Patent: February 28, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20160008390Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: September 27, 2015Publication date: January 14, 2016Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef SHAUL, Peter Tsvetkov, Julia Adler
-
Patent number: 9145559Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: October 25, 2012Date of Patent: September 29, 2015Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20140288157Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: October 25, 2012Publication date: September 25, 2014Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler